Table 1.
Clinical characteristics and laboratory data for the control and ET populations.
| Variable | Controls | ET | P |
|---|---|---|---|
| Age (years)a | 60 (43–79) | 60.5 (25–93) | NS |
| JAK2 V617F allele burden+ (%)a | N.A | 22 (0.13–49.7) | NA |
| Hb (g/L)b | 140 (11) | 141 (15) | NS |
| Leukocytes(×109/L)b | 6.4 (1.6) | 7.9 (3.5) | <0.001 |
| Platelets (×109/L)b | 251 (80) | 587 (284) | <0.001 |
| CRP (mg/L)b | 1.0 (1.7) | 1.5 (2.8) | NS |
| GDF15 (ng/mL)b | 521 (204) | 720 (737) | <0.001 |
| PTX3 (ng/mL)b | 1,432 (971) | 1,850 (1,385) | NS |
| E-selectin (ng/mL)b | 9,618 (4,823) | 11,450 (6,936) | <0.05 |
| P-selectin (ng/mL)b | 44,058 (15,388) | 135,959 (62,207) | <0.001 |
| sVEGFR1 (ng/mL)b | 632 (437) | 564 (596) | NS |
| sVEGFR2 (ng/mL)b | 3,002 (1,105) | 2,891 (1,049) | NS |
Variables are expressed as
a
median (range) or
b
median (interquartile range).
ET: essential thrombocythemia; NA: not applicable; NS: not significant; JAKV617F allele burden+: proportion of positive for Janus kinase 2 allele showing the V617F mutation; CRP: C-reactive protein; GDF15: growth differentiation factor 15; sVEGFR1: soluble vascular endothelial growth factor receptor 1; sVEGFR2: soluble vascular endothelial growth factor receptor 2.